Lundbeck moves US headquarters to Greater Boston

Nanexa has entered into a global exclusive license and collaboration agreement with Novo for the use of the PharmaShell technology platform for certain peptide-based drugs targeting obesity, type 2 diabetes and other cardiometabolic indications.

The Helsinki-based company has closed a EUR 30 million Series A round led by Hadean Ventures to take its lead candidate, a TrkB potentiator designed to deliver the benefits of psychedelics without the hallucinations, into clinical trials for major depressive disorder.

The Oslo-based radiopharmaceutical company has raised NOK 148.5 million in a private placement and retail offering to complete its Phase 2 ovarian cancer trial and prepare for Phase 3.

Elicera Therapeutics has received approval from the Swedish Medical Products Agency (Läkemedelsverket) to move its CARMA study of the CAR T-cell therapy ELC-301 in B-cell lymphoma into Phase IIa.

Novo presented Phase 3 data showing its weight management candidate CagriSema achieved greater weight loss than Eli Lilly's tirzepatide, as it outlined its 2030 ambitions at a Capital Markets Day in London, including more than five multi-blockbuster launches by 2030 and more than DKK 150 billion in risk-adjusted pipeline sales in 2035.

The European Medicines Agency's human medicines committee (CHMP) has adopted a positive opinion recommending marketing authorisation for Novo Nordisk's Frehemgo (denecimig) for haemophilia A, with or without inhibitors, in adults and children. The company says it is the first factor VIIIa mimetic offering once-monthly, once-every-two-weeks and once-weekly prophylaxis in a single-use pre-filled pen.

The US Food and Drug Administration (FDA) has accepted and granted Priority Review to Alexion, AstraZeneca's Rare Disease unit, for efzimfotase alfa as a treatment for patients with hypophosphatasia (HPP) aged 2 years and older.